ClinicalTrials.gg
RecruitingNCT06127316CDODistractUpdated Oct 21, 2026

The Effects of Heel Distraction Height on Foot Loading With Carbon Fiber Custom Dynamic Orthoses

An interventional study of Carbon Fiber Custom Dynamic Orthosis (CDO) in Traumatic Lower Limb Injury, sponsored by University of Iowa. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Iowa · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Carbon fiber custom dynamic orthoses (CDOs) and unloading ankle foot orthoses (AFOs) have shown varying levels of success in reducing forces acting on different regions of the bottom of the foot during gait. CDOs and unloading AFOs have shown differing offloading capabilities across different regions of the foots (hindfoot, midfoot, forefoot) which may be related to a distinct difference between CDOs and unloading AFOs: CDOs do not suspend, or distract, the foot away from the footplate. The purpose of this study is to determine the effects of CDOs and heel distraction height (the distance between the heel and the footplate) on limb loading and motion during gait as well as patient reported pain, and comfort.

Read the detailed description

Carbon fiber custom dynamic orthoses (CDOs) have been used to improve function, reduce pain, and offload the foot and ankle for individuals with a number of conditions affecting the lower extremity. CDOs consist of a proximal cuff that wraps around the leg just below the knee, a posterior carbon fiber strut that bends to store and return energy during mid to late stance, a semi-rigid carbon fiber footplate, and, in some cases, a foam heel wedge placed in the shoe. Unloading ankle foot orthoses (AFOs) have also been used for a number of lower extremity conditions, including traumatic injuries, in effort to reduce forces and pressure acting under the foot. Unloading AFOs have been created using many different designs, which include a proximal cuff just below the knee, a rigid strut (made of metal, plastic, etc.), and some sort of foot component (footplate, shoe, etc.).

Both CDOs and unloading AFOs have shown varying levels of success in reducing forces acting on different regions of the bottom of the foot during gait. The differences in loading may be related to a distinct difference between CDOs and unloading AFOs: CDOs do not suspend, or distract, the foot away from the footplate.

The purpose of this study is to determine the effects of CDOs and heel distraction height (the distance between the heel and the footplate) on limb loading and motion as well as patient reported pain and comfort. In this study, forces acting under the foot will be measured using wireless Loadsol insoles (Novel GMBH, St. Paul, MN) as participants walk without an orthosis (NoCDO) and with a CDO with three different posterior strut lengths resulting in three different levels of heel distraction (0cm, 1cm, 2cm) at self-selected and controlled speeds. Additionally, gait kinematic and kinetics will be measured using infrared motion capture cameras (Vicon Motion Systems Ltd., Denver, CO) and force plates (AMTI, Watertown, MA). Participants will be provided a lift for the contralateral limb to reduce the effects of leg length discrepancies during walking. Loadpad force measuring sensors (Novel GMBH, St. Paul, MN) will be used to measure forces within the CDO proximal cuff. After walking in each condition, participants will complete questionnaires concerning pain and orthosis comfort.

02

Conditions studied

  • Traumatic Lower Limb Injury

Keywords

  • Plantar Force
  • Ankle Foot Orthosis
  • Carbon Fiber Orthosis
  • Biomechanics
03

In context

Lead sponsor

University of Iowa is the lead sponsor of 279 studies on the registry; 32 are open to participants now.

Of its 45 completed or terminated interventional studies of FDA-regulated products, 40 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 18-65 years
  2. Traumatic hindfoot injury (soft tissue injury or fracture affecting the hindfoot or ankle)
  3. Mechanical pain with limb loading (>=4/10 on Numerical Pain Rating Scale)
  4. Ability to walk 50 feet at a slow to moderate pace
  5. Ability to walk without a cane or crutch
  6. Ability to read and write in English and provide written

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis with a moderate or severe brain injury
  2. Diagnosis with a physical or psychological condition that would preclude functional testing (e.g., cardiac condition, clotting disorder, pulmonary condition, etc.
  3. Ankle weakness resulting from spinal cord injury or central nervous system pathology
  4. Nerve, muscle, bone, or other condition limiting function in the contralateral extremity
  5. Rheumatoid or inflammatory arthritis
  6. Necrosis of any bones in the foot or ankle
  7. Pain of 8/10 or greater during walking
  8. Uncorrected visual or hearing impairments
  9. Require use of a knee stabilizing device to perform daily activities (i.e., Knee ankle foot orthosis, knee orthosis, etc.)
  10. Pregnancy
  11. greater than 40 kg/m2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    NoCDO

    Participants will complete study activities without a CDO

  • Experimental
    0cm Distraction

    Participants will complete study activities while wearing a CDO with 0cm of heel distraction height

    Device: Carbon Fiber Custom Dynamic Orthosis (CDO)

  • Experimental
    1cm Distraction

    Participants will complete study activities while wearing a CDO with 1cm of heel distraction height

    Device: Carbon Fiber Custom Dynamic Orthosis (CDO)

  • Experimental
    2cm Distraction

    Participants will complete study activities while wearing a CDO with 2cm of heel distraction height

    Device: Carbon Fiber Custom Dynamic Orthosis (CDO)

Interventions

  • DeviceCarbon Fiber Custom Dynamic Orthosis (CDO)

    The carbon fiber custom dynamic orthoses (CDOs) used in this study will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee. The CDO will be modular in design which will allow three carbon fiber struts of the same stiffness and differing lengths to be used to implement 0cm, 1cm, and 2cm levels of heel distraction height. A longer posterior strut will move the carbon fiber footplate away from the participants foot to create the heel distraction height.

    Also known as: Ankle Foot Orthosis (AFO)

06

What researchers measure

Primary outcomes

  1. Peak Force (forefoot)

    Plantar forces (N) will be measured across the forefoot (distal 40% of sensor) as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  2. Force Impulse (forefoot)

    Plantar force impulse (Ns) across the forefoot (distal 40% of sensor) will be calculated using the integral of the force over the stance phase as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  3. Peak Force (hindfoot)

    Plantar forces (N) will be measured across the hindfoot (proximal 30% sensor) as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  4. Force Impulse (hindfoot)

    Plantar force impulse (Ns) across the hindfoot (proximal 30% sensor) will be calculated using the integral of the force over the stance phase as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  5. Numerical Pain Rating Scale

    Pain will be assessed using a standard 11-point numerical pain rating scale, in which 0 = no pain and 10 = worst pain imaginable

    Time frame: Baseline

  6. Modified Socket Comfort Score

    Comfort scores range from 0 = most uncomfortable to 10 = most comfortable, and from 0 = least smooth to 10 = most smooth

    Time frame: Baseline

Secondary outcomes

  1. Peak Force (total foot)

    Plantar forces (N) will be measured across the total foot (100% of sensors) as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  2. Force Impulse (total foot)

    Plantar force impulse (Ns) across the total foot (100% of sensors) will be calculated using the integral of the force over the stance phase as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  3. Peak Force (midfoot)

    Plantar forces (N) will be measured across the midfoot (middle 30% of sensor) as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  4. Force Impulse (midfoot)

    Plantar force impulse (Ns) across the midfoot (middle 30% of sensor) will be calculated using the integral of the force over the stance phase as participants walk without a CDO and with each CDO.

    Time frame: Baseline

  5. Ankle Range of Motion

    Peak ankle dorsiflexion (degrees) during gait.

    Time frame: Baseline

  6. Peak Ankle Moment

    Peak ankle plantarflexion moment (Nm/kg) during gait.

    Time frame: Baseline

  7. Peak Ankle Power

    Peak ankle push-off power (W/kg) during gait.

    Time frame: Baseline

Other outcomes

  1. Semi-Structured Interview

    Participants will be asked a number of open ended questions to help determine what factors influenced their perception of each study condition.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2024 (actual). Primary completion is estimated for Aug 2027, 35 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jun 2026 → Aug 2027 and completion Jun 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 13, 2023
StartActual
Aug 16, 2024
Primary completionEst.
Aug 1, 2027was Jun 2026
CompletionEst.
Aug 1, 2027was Jun 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2026→Aug 1, 2027
Oct 21, 2026
Study completion
Jun 1, 2026→Aug 1, 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Jun 1, 2026→Aug 1, 2027
    Study completion Jun 1, 2026→Aug 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06127316
Lead sponsor
University of Iowa
Collaborators
Fabtech Systems
Responsible party
Jason Wilken (Associate Professor, University of Iowa) — Principal investigator
First posted
Nov 13, 2023
Start date
Aug 16, 2024
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Jason M Wilken, PT, PhD
Contact
jason-wilken@uiowa.edu
3193356857
Kirsten M Anderson, PhD
Contact
kirsten-m-anderson@uiowa.edu
3193530431
Jason M Wilken, PT,PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion